A 50-kD integrin-associated protein (IAP) has been reported to be associated with & integrins and to modulate their function, especially vitronectin receptor in human erythroleukemia (HEL) cells and leukocyte response integrin in neutrophils. We studied the involvement of IAP in the function of platelet p3 integrin, glycoprotein (GP) Ilb-llla complex. IAP was a widely distributed protein and was also expressed in the cells that do not have p3 integrin. Platelets from a patient with thrombasthenia, which lack GPllb and Ilia, expressed IAP as well as normal platelets. Neither platelet aggregation nor intracellular Ca2+ elevation after stimulation was influenced by the anti-IAP antibody, B6H12, which was reported NTEGRIN-ASSOCIATED protein (IAP) is a 50-kD membrane glycoprotein (GP) that was originally reported to be physically associated with p3 integrin because IAP was copurified and coimmunoprecipitated with avo3 vitronectin receptor in placenta or with a I I b P 3 , GPIIb-IIIa complex in platelets.' IAP is a widely distributed protein among hematopoietic cells.' IAP is identical to an Rh-related antigen CD47 that is reduced in R h n u l l erythrocytes' and is also identical to an ovarian tumor marker, OVTL3 antigen (OA3).3 The cDNA of IAP has been cloned, and its deduced amino acid sequence showed that IAP has five transmembrane spanning regions and one Ig-like extracellular loop,' suggesting that it could be involved in cell adhesion or signal-transducing pathways. Previous reports showed that adhesion of human erythroleukemia (HEL) cells via the vitronectin receptor was blocked by anti-IAP antibody,' and neutrophil function such as oxidative burst mediated by leukocyte response integrin was induced or inhibited by anti-IAP a n t i b~d y .~.~ Calcium ion influx in endothelial cells upon adhesion to fibronectin or vitronectin surface was also inhibited by the same antibody.' All these data indicate that IAP is an integrin-mediated signal transducing molecule or that IAP can modulate the function of some of the p3 integrins.
NTEGRIN-ASSOCIATED protein (IAP) is a 50-kD membrane glycoprotein (GP) that was originally reported to be physically associated with p3 integrin because IAP was copurified and coimmunoprecipitated with avo3 vitronectin receptor in placenta or with a I I b P 3 , GPIIb-IIIa complex in platelets.' IAP is a widely distributed protein among hematopoietic cells.' IAP is identical to an Rh-related antigen CD47 that is reduced in R h n u l l erythrocytes' and is also identical to an ovarian tumor marker, OVTL3 antigen (OA3). 3 The cDNA of IAP has been cloned, and its deduced amino acid sequence showed that IAP has five transmembrane spanning regions and one Ig-like extracellular loop,' suggesting that it could be involved in cell adhesion or signal-transducing pathways. Previous reports showed that adhesion of human erythroleukemia (HEL) cells via the vitronectin receptor was blocked by anti-IAP antibody,' and neutrophil function such as oxidative burst mediated by leukocyte response integrin was induced or inhibited by anti-IAP a n t i b~d y .~.~ Calcium ion influx in endothelial cells upon adhesion to fibronectin or vitronectin surface was also inhibited by the same antibody.' All these data indicate that IAP is an integrin-mediated signal transducing molecule or that IAP can modulate the function of some of the p3 integrins.
However, there is no report as to whether IAP could activate or modulate platelet p3 integrin, GPIIb-IIIa complex.
GPIIb-IIIa complex is a major platelet integ~in"~ that is a heterodimer o f two subunits, ie, allb and P3. It acts as a fibrinogen receptor resulting in platelet aggregation and also mediates platelet adherence to components of the subendothelial matrix. However, resting platelets do not bind soluble fibrinogen. GPIIb-IIIa complex acquires the ability to bind adhesive proteins when platelets are stimulated by appropriate agonists (eg, thrombin, adenosine diphosphate [ADP], or thromboxane A'). These alterations in ligand-binding affinity of the GPIIb-IIIa complex are believed to be a result of the conformational changes in its extracellular domain?"' The GPIIb-IIIa complex can be converted to an active state by binding of certain monoclonal antibodies or by preexposure to Arg-Gly-Asp (RGD)-containing peptides." Under physiologic conditions, on the other hand, extracellular agonists initiate cytoplasmic signals that then cause the changes in conformation and ligand-binding affinity of the comp l e~. " . '~ Results from recent report^*,^*^^"' suggest that physiologically relevant signals are transduced to the integrin through its cytoplasmic domains, probably by unknown associated factors. However, the precise mechanisms behind this effect are largely unknown. IAP is one of the candidates for the modulator of the function of GPIIb-IIIa complex because it is associated with GPIIb-IIIa complex in platelets and can modulate other integrin functions. In this study, we investigated whether IAP could influence the expression and function of GPIIb-IIIa complex in platelets, in a relevant cell line (HEL cells), and in transfected Chinese hamster ovary (CHO) cells.
MATERIALS AND METHODS

Materials.
Hybridoma cells producing anti-IAP monoclonal antibody, B6H12,' were purchased from American Type Culture Collection (ATCC; HB-9771, Rockville, MD). The antibody was punfied from mouse ascites using HiTrap protein G affinity column (Pharmacia, Uppsala, Sweden) according to the manufacturer's instruction. P2 (anti-GPIIb-IIIa) and SZ2 (anti-GPIba) were purchased from Immunotech (Marseille, France). LM609 (anti-vitronectin receptor)" was kindly provided by Dr D.A. Cheresh (Scripps Research Institute, La Jolla, CA). Control IgG (mouse myeloma IgG) was from Organon Technica (West Chester, PA). Fluorescein isothiocyanate (HTC)-conjugated goat F(ab'), antimouse IgS were from TAG0 (Burlingame, CA). F'ITC-conjugated streptavidin was from Caltag (South San Francisco, CA). Aequorin was from Wake pure Chemical (Osaka, Japan). Propidium iodide (PI), ADP, epinephrine, phorbol myristate acetate (PMA), poly-L-lysine, and Crys- tal Violet were purchased from Sigma (St Louis, MO). Collagen was purchased from Nycomed (Munchen, Germany). NHS-LC-biotin was from Pierce (Rockford, IL). Prostaglandin (PG) EI was from Ono Pharmaceutical (Osaka, Japan). Human a-thrombin was a gift from Green Cross (Osaka, Japan). Human fibrinogen was purified as previously described." Vitronectin and lipofectin were from GIBCO BRL (Gaithersburg, MD).
Flow cytometric analysis. Platelets from healthy volunteers and a patient with thrombasthenia were obtained after informed consent was obtained according to the declaration of Helsinki. Flow cytometric analysis was performed as described previously?o.21 Platelets were fixed with 1% paraformaldehyde in HEPES buffer (137 m o l / L NaCI, 2.7 mmoVL KCI, 3.3 mmoVL NaH2P04, 1 mmoVL MgC12, 4 mmoVL HEPES, and 5.6 mmoVL glucose, pH 7.4), washed, and suspended at 2 X 107/mL in the buffer described above. Each aliquot (50 pL) was incubated with the appropriate first antibody (10 pg/ mL). After washing, platelets were incubated again with FITC-conjugated goat F(ab'), antimouse Igs. Each incubation was performed on ice for 30 minutes. Cells were finally washed and analyzed using a flow cytometer (Cytron Absolute; Ortho Diagnostic System, Raritan, NJ). Human neutrophils were isolated from heparinized blood using MonoPoly Resolving Media (Flow Laboratories, North Ryde, Australia) according to the manufacturer's instructions and the bottom layer was also collected as an erythrocyte fraction. For cases of neutrophils, erythrocytes, and cultured cells (CHO, HL-60, and 293 cells), cells were stained in the same manner except that they were not fixed and were incubated in Hank's Balanced Salt Solution with Caz+ (HBSS) containing 1% fetal bovine serum (FBS) and 0.1% NaN3 instead of HEPES buffer. After the last wash, some cells were also stained with 1 pg/mL PI to exclude permeabilized dead cells.
Platelet aggregation and intracellular ionized calcium. Platelet aggregation study was performed as described previously.22 Platelet counts in platelet-rich plasma (PRP) were adjusted to 3 X 1@/pL. PRP was incubated with B6H12, anti-GPIIb-IIIa, or control mouse IgG (40 pg/mL) for 5 minutes before the addition of agonists (ADP, collagen, or epinephrine). Aggregation was measured with a platelet aggregometer (Chrono-Log, Havertown, PA).
Concentration of the intracellular calcium ion was measured using photoprotein Aequorin. Aequorin was loaded to platelets as described previ~usly?~ Change in the Aequorin luminescence during platelet aggregation was recorded using a Platelet Ionized Calcium Aggregometer (PICA; Chrono-Log).
Expression vectors and transfection to CH0 cells. The entire coding lesion of the IAP cDNA was amplified from human neutrophil cDNA by means of a polymerase chain reaction (PCR) method using a DNA thermal cycler (Perkin Elmer Cetus, Norwalk, CT). Primers were designed according to the published sequence' (Biosynthesis, Lewisville, TX). PCR products were cloned into pGEM-T vector (Promega, Madison, W) and the sequence was verified using an automated DNA sequencer (Model 373A; Applied Biosystems Inc, Foster City, CA). The cDNA was ligated to a plasmid expression vector, pBK-EF, which contains a powerful promotor from human elongation factor-la (EF-la) gene24 and neomycinresistant gene. EF-la promotor was also cloned using the PCR method and replaced with cytomegalovirus (CMV) promotor in a plasmid pBK-CMV (Stratagene, La Jolla, CA). cDNAs of platelet GPIIb and IIIa were cloned from the HEL cell cDNA library using a colony hybridization method according to the published seq u e n c e~.~~.~~ C H 0 cells were grown in a mixture of D-MEM/F-12 (GIBCO BRL) supplemented with 10% FBS, 200 U/mL penicillin, and 200 p g h L streptomycin under 5% CO, at 37°C. Transfection was performed using lipofectin and permanent transfectants were selected with G418, as described previously." To establish the CH0 cells that stably express both GPIIb-IIIa complex and IAP, stable cells expressing GPIIb-IIIa were firstly established and the cDNA of IAP was transfected into these cells. Ten days after culture in (3418-containing medium, cells were selected by reactivity to the antibody B6H12 using an immunomagnetic cell selection system (Dynal, Oslo, Norway). Cells were harvested and incubated with B6H12, followed by Dynabeads with covalently bound antimouse IgG. Positive cells were then collected using a magnetic particle concentrator and cultured again for 3 to 4 days. These procedures were repeated three times.
Measurement of jbrinogen binding using a jZow cytometer. Fibrinogen binding to platelets and CH0 cell transfectants in solution was measured using a flow cytometer?8 Cells were washed and suspended in HEPES buffer containing 1 mg/mL bovine serum albumin (BSA) and 1 mmom CaCI,. We added IO pmoVL PMA for stimulated cells or 1 pmoVL PGEl for nonstimulated cells and various concentration of biotinylated fibrinogen. The mixture was then incubated for 15 minutes at room temperature without stimng. The final incubation volume was 50 pL and the cell concentration was 4 X 102/pL. Fibrinogen was biotinylated with NHS-LC-biotin, as described previously?o Five microliters of streptavidin-FITC conjugate was then added and the mixture was incubated for an additional 15 minutes. Finally, 500 pL of HEPES buffer containing 1 pg/mL PI was added and the mixture was directly analyzed using a flow cytometer. PI-negative cells and single particles especially for platelets were gated. A control aliquot for each reaction was prepared under the same condition except that 5 mmoVL EDTA was added instead of CaClz. The difference of mean fluorescence intensity between in the presence of Ca2+ and EDTA was estimated as a specific binding.
Cell adhesion assay. Adhesion assays of HEL cells and transfected CH0 cells were performed according to a previously published with a slight modification. Ninety-six-well enzyme immunoassay/radioimmunoassay (EIAIRIA) plates (Costar, Cambridge, MA) were coated with 100 pL of HBSS containing 20 pg/mL fibrinogen, 5 pg/mL vitronectin, 100 pg/mL BSA, or 100 pg/mL poly-L-lysine overnight. Plates were washed three times with HBSS and blocked with 1 mg/mL BSA. A total of 1 X lo5 cells were added per well in the presence of 40 pg/mL of the appropriate antibody or 10 mmoVL EDTA. The plates were centrifuged at lOOg for 5 minutes and then incubated at 37°C for 1 hour. Plates were washed four times with HBSS containing 1 mg/mL BSA to remove the unbound cells and the bound cells were fixed with 1% paraformaldehyde. Cells were stained with 0.5% Crystal Violet for 15 minutes, rinsed, and solubilized with 1% sodium dodecyl sulfate (SDS). The absorbance at 540 nm was measured on a microtiter plate reader (SLT-Lab Instruments, Salzburg, Austria).
RESULTS
Expression of IAP in a variety of cells and thrombasthenic platelets.
We prepared an anti-IAP monoclonal antibody, B6H12, from the hybridoma cell line that was purchased from ATCC. The antibody recognized one relatively broad band at approximately 50 kD from platelets and neutrophil membrane proteins using immunoblott analysis (data not shown), confirming the reactivity of the antibody.' Using this antibody, we first analyzed the expression of IAP in a variety of cells using a flow cytometer (Fig 1) The expression of IAP was also analyzed in platelets from a patient with thrombasthenia, which is an inherited bleeding disorder. Thrombasthenic platelets do not aggregate because the patient's platelets lack the GPIlb-IIIa complex. As shown in Fig 2, GPllb-IIIa complex was reduced in the patient's platelets. However, the expression of IAP was observed as well as in normal platelets. These data indicate that IAP can be expressed independently even though the expression of GPIIb-IIIa complex was impaired.
Efects B6H12 on platelet function. We next determined the effects of anti-IAP antibody on several platelet functions. The antibody B6H12 was reported to have an epitope on the extracellular Ig-like loop of IAP' and to inhibit the function of vitronectin receptor in HEL cells,3 the oxidative burst mediated by leukocyte response integrin in neutrophils." or the integrin-mediated Ca" influx in endothelial cells? thus acting as an inhibitory antibody for IAP. Platelet aggregation was measured in the presence of the antibody. However, as shown in Fig 3, platelet aggregation induced by ADP, collagen, or epinephrine was not influenced by B6H12 (up to 100 pg/mL) at all. although the anti-GPIlbIlla complex antibody P2 completely inhibited the aggregation. Intracellular calcium elevation after thrombin or collagen stimulation was also measured using the Aequorin method. but was not influenced by the antibody B6H 12 (Fig   4) . Clot retraction using whole blood was not also inhibited by B6H 12 (data not shown). These data indicate that B6H 12. an inhibitory antibody for IAP, does not inhibit platelet function, whereas previous reports showed that the antibody does inhibit integrin function in HEL cells. neutrophils. and endothelial cells.
E.rpressior1 rfIAP o n C H 0 cells. To determine whether the expression of IAP and GPIIb-llla complex could affect each other, expression studies in C H 0 cells were performed. We first prepared C H 0 cells stably expressing GPllb-IIla complex and transfected IAP cDNA into these cells. C H 0 cells stably expressing both IAP and GPllb-IIIa complex were established by selection for the reactivity of B6H12, as described in the Materials and Methods. Although IAP was expressed additionally, the expression level of GPIIbIlla complex was not changed either in transient or stable cells (Fig S) . In the other experiments, we prepared the C H 0 cells stably expressing IAP first and then transfected cDNA of GPIIb-IIIa complex. The expression level of the GPTIbIlla complex was compared with that in the parental C H 0 cells transfected with GPllb-Illa cDNA. However, the expression level of GPllb-llla was not affected by the presence of IAP (data not shown). These data indicate that the expression of IAP and GPIIb-llla complex was regulated independently.
Fibrinogen binding t o the transfec1ed C H 0 cells. For these two types of C H 0 cell transfectants (expressing GPIIbIlIa complex alone or expressing both IAP and GPIIb-IIIa complex), fibrinogen binding in solution was measured using a flow cytometer. GPIIb-IIIa complex was observed in the immunoprecipitate by B6H12 from the latter C H 0 cell lysates (data not shown). Platelets were used as a positive control and the experiments were performed at a very low concentration to avoid cell aggregation. We tried to stimulate cells with PMA because it is reported that protein kinase C activity closely correlates with agonist-induced activation of GPIIb-llla complex in platelets'' and at least several kinases participating in the intracellular signalling should also be activated in C H 0 cells. Using this method, when we added the increasing amount of fibrinogen, a small fluorescence shift was observed even in the parental C H 0 cells, depending on the concentration of fibrinogen, which was probably due to the nonspecific binding. Therefore, a control experiment was prepared in the buffer containing EDTA instead of calcium for each reaction and the difference of the mean fluorescence intensity was estimated as specific fibrinogen binding. In the control platelets, a fluorescence shift due to the fibrinogen binding was observed when the cells were stimulated. In contrast, in the GPIIb-IIIa-CH0 cells, fibrinogen binding was not observed at all despite coexpression with IAP and cell stimulation (Fig 6A) . The changes of relative mean fluorescence intensity in the various concentrations of fibrinogen are shown in Fig 6B. We concluded that IAP does not facilitate soluble fibrinogen binding to the CH0 cells expressing GPIIb-IIIa complex.
Cell adhesion on jibrinogen-coated surjke. We finally examined the effects of IAP and anti-1AP antibody on cell 
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adhesion to fibrinogen-coated surface via the GPIIb-ma complex. GPIIb-IIIa complex in the transfected recombinant form or on relevant megakaryocytic cells has the ability to promote cell adhesion to a fibrinogen-coated surface?9 although GPIIb-IIIa complex can bind soluble fibrinogen only on activated platelets. Furthermore, all of the reported effects of anti-IAP antibody were observed in a cell adhesion assay of the immobilized adhesive protein. We examined the adhesion of HEL cells onto a fibrinogen-or vitronectincoated surface (Fig 7) . HEL cells express GPIIb-IIIa complex, and IAP.
The inhibitory antibody, B6H12, also blocked the adhesion to vitronectin surface in our hands, confirming previous report^.^ However, adhesion to fibrinogen surface was not influenced at all. Adhesion of the transfected CH0 cells onto fibrinogen surface was also examined (Fig 8) . These two kinds of CH0 cells (expressing GPIIb-IIIa complex alone or both GPIIb-IIIa complex and IAP) expressed comparable levels of GPIIb-IIIa complex. Adhesion to the immobilized fibrinogen was not significantly different between GPIIb-IIIa-CH0 and GPIIb-IIIa plus IAP-CH0 cells. The antibody B6H12 did not show inhibitory effects for both cells. As a control experiment, the effect of B6H 12 on the adhesion of these CH0 cells onto vitronectin surface via hamster a,P3 was tested. B6H12 showed an inhibitory effect when the cells expressed human IAP.
DISCUSSION
Our first conclusion in this study is that the expression of IAP is regulated independently with that of GPIIb-IIIa complex. I A P was fully expressed in the cells that do not have p3 integrins and in thrombasthenic platelets that lack the GPIIb-IIIa complex.30 IAP and GPIIb-IIIa complex did not affect the expression level of each other in the transfected CH0 cells. In many cases, the complexed form of the membrane surface proteins requires the presence of all subunits for their complete surface expression, and each subunit cannot localize stably on the cell surface independently, eg, in the case of GPIIb-IIIa or GPIb-V-IX complex32.33 in platelets. However, our data show that association of IAP and GPIIb-IIIa complex is not critical for their surface expression. Brown et al' first showed that GPIIb-IIIa complex can be coimmunoprecipitated with IAP by anti-IAP antibody, but the stoichiometry of the association is not yet known. I A P and GPIIb-IIIa complex are expressed on the cell surface through an independent pathway and, after that, some might associate on the surface. The second conclusion is that IAP does not influence the function of GPIIb-IIIa complex. Platelet aggregation or intracellular Ca" elevation was not inhibited by B6H12. GPIIb-IIIa complex or in functional form even if associated. Therefore, we performed the experiments using coexpression of human IAP. In platelets and possibly in HEL cells, IAP and GPllb-IIIa complex are both present under the natural conditions. However, we could not obtain evidence that IAP is involved in the function of GPllb-IIIa complex under any experimental conditions. The binding of soluble fibrinogen requires a significant change in the affinity of the GPIIb-IIla
The lower affinity of the receptor is sufficient for cell attachment onto immobilized fibrinogen because adhesion of HEL cells or C H 0 cells with GPIlb-llla complex of reduced affinity can occur?* However, IAP did not affect the GPIlb-IlIa complex of either affinity status. In contrast, the adhesion of HEL cells or the C H 0 cells expressing human IAP onto vitronectin surface was inhibited, confirming the previous report of Lindberg et al. ' They showed that the binding of vitronectin-coated beads to HEL cells via a& receptor was blocked by B6H 12. They also showed that, in CH0 cells, once cells were transfected with human IAP, which probably can associate with hamster a,&, B6H12 then inhibited the binding to vitronectin via hamster a,&, whereas B6H12 did not inhibit the binding of parental C H 0 cells to vitronectin. In our experiments, B6H12 did not inhibit the C H 0 cell binding to fibrinogen via GPIIb-IIla complex, even though human IAP was transfected to C H 0 cells (Fig 8) . Their group also indicated that IAP does not associate with all integrins, did not affect the binding of HEL cells to fibronectin via aspI, and did not affect PI-or &depen-dent function of leukocytes.'.' All these data suggest that the functional involvement of IAP is receptor type-specific and is restricted even among 0' integrins. The functional significance of the association of IAP and GPIIb-IIIa complex in platelets is not certain at present. However, the discrepancy of the effects of IAP on the function of avo3 and GPIlb-IIIa complex would be of interest when the activation mechanisms of these / 3 ' integrins are considered. Schwartz et a16
showed the inhibitory effects of B6H12 on a slow Ca" influx into endothelial cells on adhesion to fibronectin or vitronectin surface, suggesting that IAP is closely associated with calcium channel activity. We previously reported that GPllb-IIIa complex is involved in Ca" influx in It would be an attractive hypothesis that IAP itself may be a channel molecule because it has a multi-membranespanning structure. However, B6H 12 did not show any effects on platelet intracellular Ca" elevation.
The For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From cause recombinant GPIIb-IIIa complex in the transfected heterologous cells cannot be converted to the active state. We have begun exploring the involvement of already known molecules in the functional modulation of GPIIb-IIIa complex and consider IAP to be a good candidates, although it is not known whether IAP is associated with the integrin at its extracellular or cytoplasmic domain. However, we could not obtain supportive evidence in this study. We performed similar experiments with another molecule called cell adhesion regulator (CAR)," which was reported to be a myristoylated and tyrosine-phosphorylated cytoplasmic protein able to increase cell adhesion to a collagen type l-coated surface. However, we could not observe any effects of the CAR molecule on the function of GPIIb-IIIa complex. The affinity modulation of GPIIb-IIIa complex might be regulated by as yet unknown but probably megakaryocyte-platelet lineagespecific novel molecules. 
